After upsized $400 million IPO, Kardigan rises in Nasdaq debut
Corroborated by 2 sources from 2 publishers
globalbusiness5h ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, the strong market debut underscores renewed investor appetite for biotech companies with advanced clinical programs and promising drug pipelines as improving market conditions reopen the IPO window for the sector.